Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426784 | 0.94 | HCRTR1 (0.76) | HCRTR1HCRTR2 | |
| SCHEMBL4427404 | 0.92 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL6910107 | 0.90 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL6788718 | 0.90 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4425848 | 0.90 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL4428212 | 0.90 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL6792059 | 0.88 | HCRTR1 (0.79) | HCRTR1HCRTR2 | |
| SCHEMBL6792236 | 0.87 | HCRTR1 (0.89) | HCRTR1HCRTR2 | |
| SCHEMBL4436499 | 0.86 | HCRTR1 (0.89) | HCRTR1HCRTR2 | |
| SCHEMBL6787556 | 0.86 | HCRTR1 (0.84) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | claimed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | claimed |
| WO-2001068609-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2002-02-21 | — | — | WO | claimed |
| CN-101400348-A | Tetrahydroisoquinoline derivatives for improving memory function | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-01 | — | — | CN | disclosed |
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1998774-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES TO ENHANCE MEMORY FUNCTION | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007105177-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES TO ENHANCE MEMORY FUNCTION | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082394-A1 | Tetrahydroisoquinoline Derivatives to Enhance Memory Function | GRIN2A, BDNF, GRIN2C | HCRTR1 86/4885HCRTR2 53/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.